Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 17, 2026 | June 22, 2026 |
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director · Chief Executive Officer | May 11, 2017 | May 13, 2017 |
| IPI Legacy Liquidation CoIMPL · Entity 15659 | Director · COB, CEO and President | February 14, 2023 | February 16, 2023 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 236,200 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 35,700 · Balance 236,200 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2036-06-17 | Direct | 53,600 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Aralez Pharmaceuticals Inc.
Report date May 11, 2017 · Filed May 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 3,787,610 |
Reported balance
After 2017-05-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-11 · Grant · Acquired 218,380 · Balance 3,787,610 F1: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company. F2: Includes 2,027,668 shares of Common Stock and 1,759,942 Restricted Stock Units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2027-05-11 | Direct | 252,316 |
Reported balance
After 2017-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-11 · Grant · Acquired 252,316 · Balance 252,316 F3: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company.
F2: Includes 2,027,668 shares of Common Stock and 1,759,942 Restricted Stock Units.
F3: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company.
IPI Legacy Liquidation Co
Report date February 14, 2023 · Filed February 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2033-02-13 | Direct | 200,000 |
Reported balance
After 2023-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-14 · Grant · Acquired 200,000 · Balance 200,000 F1: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,709 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 22,709 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 21:07 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001248144-26-000003 · form4-06242026_090645.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2036-06-21 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:07 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001248144-26-000003 · form4-06242026_090645.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,709 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001248144-26-000001 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:09 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001248144-26-000001 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,200 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:45 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 25,600 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001248144-25-000004 · form4-10242025_081019.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2035-10-22 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:45 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 4,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001248144-25-000004 · form4-10242025_081019.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,609 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001562180-25-004723 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2035-06-10 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004723 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,500 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:12 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 13,044 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-24-018074 · form4-06242024_110605.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,044 Underlying: Common Stock · 13,044 shares Expires 2034-06-23 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:12 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018074 · form4-06242024_110605.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,342 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001562180-24-004901 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004901 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,800 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:19 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 3,487 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-058474 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,487 Underlying: Common Stock · 3,487 shares Expires 2033-10-10 F4 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:19 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058474 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,168 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. F3 · balance_after: Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-23-004956 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:07 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004956 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,800 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:19 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-23-010243 · doc4.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on March 14, 2023 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on February 14, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:31 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001209191-22-042308 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2032-07-14 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:31 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042308 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:56 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-22-004973 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2032-06-08 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:56 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004973 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,800 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 17:01 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0001209191-22-005445 · doc4.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on February 26, 2022 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on January 26, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 17:23 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | PurchaseCommon Stock | 600 | $15.89 | $9,531.90 |
DisclosureSEC source: 0001209191-21-052595 · doc4.xml · nonDerivative · entry 3 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.81 to $15.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 17:23 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | PurchaseCommon Stock | 2,197 | $14.91 | $32,751.34 |
DisclosureSEC source: 0001209191-21-052595 · doc4.xml · nonDerivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,400 F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.69 to $15.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 17:23 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | PurchaseCommon Stock | 17,203 | $13.81 | $237,506.34 |
DisclosureSEC source: 0001209191-21-052595 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,203 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.435 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 20, 2021 Filed Jul 26, 2021 17:58 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.16 | $0.00 |
DisclosureSEC source: 0001209191-21-048217 · doc4.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · COB, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares on August 22, 2021 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on July 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:32 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-21-041579 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:32 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041579 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,250 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001562180-21-004026 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2031-06-02 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004026 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,100 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:13 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-20-037077 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:13 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037077 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,250 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 22:39 UTC Amendment | TALPHERA, INC. ACRX · Entity 7102 | PurchaseCommon Stock | 100,000 | $1.29 | $128,900.00 |
DisclosureSEC source: 0001209191-20-036749 · doc4a.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,750 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $1.27 to $1.30 on June 15, 2020. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 22:01 UTC | TALPHERA, INC. ACRX · Entity 7102 | PurchaseCommon Stock | 100,000 | $1.29 | $128,900.00 |
DisclosureSEC source: 0001209191-20-036729 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,750 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $1.27 to $1.30 on June 15, 2020. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0001562180-20-004354 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2030-06-05 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:16 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004354 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,400 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 11:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | PurchaseCommon Stock | 50,000 | $3.41 | $170,500.00 |
DisclosureSEC source: 0001562180-19-005622 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,700 F1 · kind: The purchase reported in this Form 4 was made on the open market. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.37 to $3.44, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:00 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039018 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:00 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039018 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-19-003432 · primarydocument.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003432 · primarydocument.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:39 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0000899243-18-030946 · doc4.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-12-12 F1 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 22:19 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-18-037854 · doc4.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service to the Company. F2 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 21:17 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001437749-17-011357 · rdgdoc.xml · derivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-14 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors. F3 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:53 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantEmployee Stock Option (right to buy) · Derivative | 252,316 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032416 · a4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,316 Underlying: Common Shares, without par value · 252,316 shares Expires 2027-05-11 F3 · derivative.exercise_date: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:53 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 218,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032416 · a4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,787,610 F1 · kind: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company. F2 · balance_after: Includes 2,027,668 shares of Common Stock and 1,759,942 Restricted Stock Units. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:16 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 500,000 | $2.46 | $1,230,950.00 |
DisclosureSEC source: 0001104659-17-017606 · a4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,569,230 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.305 to $2.600. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.